Department of Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.
J Antimicrob Chemother. 2021 Apr 13;76(5):1205-1214. doi: 10.1093/jac/dkab018.
To investigate the in vitro activity of antibiotics against clinical Elizabethkingia anophelis isolates and to find a suitable antibiotic combination with synergistic effects to combat antibiotic-resistant E. anophelis and its associated biofilm.
E. anophelis isolates were identified by 16S rRNA sequencing; 30 strains with different pulsotypes were identified and the MIC, antibiotic resistance mechanism, antibiotic combination activity and killing effects of antimicrobial agents on biofilms of these strains were determined.
All E. anophelis isolates were susceptible to minocycline and cefoperazone/sulbactam (1:1). More than 90% of clinical isolates were susceptible to cefoperazone/sulbactam (1:0.5), piperacillin/tazobactam and rifampicin. Some novel mutations, such as gyrA G81D, parE D585N and parC P134T, that have never been reported before, were identified. The synergistic effect was most prominent for the combination of minocycline and rifampicin, with 93.3% of their FIC index values ≤0.5, and no antagonism was observed using the chequerboard method. This synergistic effect between minocycline and rifampicin was also observed using time-killing methods for clinical E. anophelis isolates at both normal inoculum and high inoculum. Twenty-nine isolates tested positive for biofilm formation. Minocycline remained active against biofilm-embedded and biofilm-released planktonic E. anophelis cells; however, the enhanced effect of minocycline by adding rifampicin was only observed at 24 h (not at 72 and 120 h).
Although E. anophelis was resistant to many antibiotics and could exhibit biofilm formation, minocycline showed potent in vitro activity against this pathogen and its associated biofilm.
研究抗生素对临床伊丽莎白菌属分离株的体外活性,并寻找具有协同作用的合适抗生素组合,以对抗耐药性伊丽莎白菌属及其相关生物膜。
通过 16S rRNA 测序鉴定伊丽莎白菌属分离株;鉴定了 30 株不同脉冲型的菌株,并测定了这些菌株的 MIC、抗生素耐药机制、抗生素组合活性以及抗菌药物对生物膜的杀菌效果。
所有伊丽莎白菌属分离株均对米诺环素和头孢哌酮/舒巴坦(1:1)敏感。超过 90%的临床分离株对头孢哌酮/舒巴坦(1:0.5)、哌拉西林/他唑巴坦和利福平敏感。鉴定出一些以前从未报道过的新型突变,如 gyrA G81D、parE D585N 和 parC P134T。米诺环素和利福平的协同作用最为显著,其 FIC 指数值的 93.3%≤0.5,棋盘法未观察到拮抗作用。在正常接种和高接种量下,米诺环素和利福平对临床伊丽莎白菌属分离株的时间杀伤法也观察到这种协同作用。29 株分离株被检测为生物膜形成阳性。米诺环素对生物膜包埋和生物膜释放的浮游伊丽莎白菌细胞仍保持活性;然而,仅在 24 小时(而不是在 72 和 120 小时)观察到添加利福平对米诺环素的增强作用。
尽管伊丽莎白菌属对许多抗生素具有耐药性,并能表现出生物膜形成,但米诺环素对该病原体及其相关生物膜表现出强大的体外活性。